Abstract Number: PB2129
Meeting: ISTH 2020 Congress
Theme: Venous Thromboembolism and Cardioembolism » Cancer Associated Thrombosis
Background: Patients with Hodgkin Lymphoma(HL) have a high risk of VTE. However, the prophylaxis with LMWH do not prevent all TE thus routine laboratory monitoring is not recommended for LMWH. The identification of high-risk group of patients and the adequate laboratory control for preventing TE are still important and actual problems.
Aims: Examine the state of hemostatic system in primary patients and during the therapy.
Methods: 29 primary patients(median 31yr,18-60 yrs,13 men,16 women), staging by Ann Arbor II-12,III-7,IV-11, were enrolled in this study. The number of thrombotic RF by Khorana predictive model from 1 to 4. The patients were treated by ВЕАСОРР-14. 24 patients receive LMWH 70-113IU/kg 2 times/day,6 patients have no anticoagulation therapy. Blood samples were collected after 4 hours after LMWH injection. ATIII, Hageman-factor-dependent fibrinolysis and D-dimer levels(DD), and the global assays Thrombodynamics (TD) and Thromboelastography(TEG) were performed to evaluate the hemostatic state of patients on diagnosis and during the 6 cycles of chemotherapy. Anti-Xa activity was used to monitor the anticoagulant activity.
Results: Hypercoagulation was detected in primary patients by TD(45%)and TEG(55%).DD were higher in 33% of patients.In 59% patients lysis time were extended, patients with high risk of TE had significant (p< 0.05)longer lysis time then patients with medium risk(41min&18min respectively).
Throughout the chemotherapy cycles in patients with ineffective LMWH prophylaxis(Anti-Xa< 0,5)was revealed the significant(p< 0.05)increase in TD and in DD compared to patients with effective prophylaxis(min 62 - max 5109ng/ml and min 53 - max 3571ng/ml respectively).
Despite LMWH prophylaxis the DD was significantly(p< 0.05)increased from 1st(min 71-max 5109) to 6th cycle (min 79-max 4376)of chemotherapy.
Conclusions: Primary patients with HL revealed hypercoagulation by TD,TEG and had extended lysis time before chemotherapy. The combination of TD, TEG, DD, lysis time and thrombotic RF is prospective in indicating high-risk group and monitoring and correction of LMWH prophylaxis in patients with HL.
To cite this abstract in AMA style:
Poletaev A, Balandina A, Seregina E, Shitareva I, Orel E, Kravchenko S, Ataullakhanov F. Haemostatic State in Hodgkin Lymphoma Patients [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/haemostatic-state-in-hodgkin-lymphoma-patients/. Accessed May 20, 2024.« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/haemostatic-state-in-hodgkin-lymphoma-patients/